This inventor holds 4 USPTO granted patents and 3 published patent applications, plus 2 CIPO patents and 3 EPO patents. Top assignees: Glaxosmithkline Intellectual Property (No.2) Limited, Glaxosmithkline Intellectual Property Development Limited. Active years: 2015-2022.
Location History:
- King of Prussia, PA (US) (2015)
- Collegeville, PA (US) (2020 - 2022)
Company Filing History:
3 out of 95 
1 out of 240 
Years Active: 2015-2022
Title: **Lamont Roscoe Terrell: Innovator in TRPV4 Antagonists**
Introduction
Lamont Roscoe Terrell is an accomplished inventor based in Collegeville, Pennsylvania. With a total of four patents to his name, Terrell has made significant contributions in the field of pharmaceutical research, particularly focusing on TRPV4 antagonists. His inventions are aimed at enhancing the effectiveness of medications that target specific neurological and pathophysiological conditions.
Latest Patents
Among his latest patents, Terrell has developed innovatively designed pyrrolidine sulfonamide analogs, which are utilized as TRPV4 antagonists. The present invention describes not only these analogs but also the pharmaceutical compositions containing them and their potential applications in therapeutic treatments.
Career Highlights
Throughout his career, Terrell has worked with notable organizations in the pharmaceutical industry. He has had key roles at GlaxoSmithKline Intellectual Property (No.2) Limited and GlaxoSmithKline Intellectual Property Development Limited, where he contributed to the advancement of drug development and intellectual property strategies.
Collaborations
In his professional journey, Terrell has collaborated with esteemed colleagues such as Edward J. Brnardic and Carl A. Brooks. These partnerships have fostered an environment of innovation, leading to breakthroughs in the pharmaceutical domain and enriching the scientific community’s understanding of TRPV4 antagonists.
Conclusion
Lamont Roscoe Terrell exemplifies the spirit of innovation within the pharmaceutical industry. His extensive research and patent portfolio signify his commitment to improving healthcare outcomes through novel therapeutic strategies. As he continues to explore the potential of TRPV4 antagonists, his work remains a testament to the powerful impact of dedicated inventors on society.